NASDAQ:IPSC Century Therapeutics Q2 2025 Earnings Report $2.12 -0.16 (-7.02%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$2.13 +0.01 (+0.71%) As of 05/19/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Century Therapeutics EPS ResultsActual EPS-$0.38Consensus EPS -$0.38Beat/MissMet ExpectationsOne Year Ago EPSN/ACentury Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.03 millionBeat/MissN/AYoY Revenue GrowthN/ACentury Therapeutics Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 14, 2025Conference Call Time4:00PM ETUpcoming EarningsCentury Therapeutics' Q2 2026 earnings is estimated for Thursday, May 21, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Century Therapeutics Earnings HeadlinesCentury Therapeutics (NASDAQ:IPSC) Lowered to Sell Rating by Wall Street ZenMay 16, 2026 | americanbankingnews.comCorbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of DirectorsMay 14, 2026 | globenewswire.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors. | American Alternative (Ad)Century Therapeutics (IPSC) to Release Quarterly Earnings on ThursdayMay 14, 2026 | americanbankingnews.comCentury Therapeutics Reports First Quarter Financial Results and Business UpdatesMay 13, 2026 | globenewswire.comH.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)May 2, 2026 | finance.yahoo.comSee More Century Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email. Email Address About Century TherapeuticsCentury Therapeutics (NASDAQ:IPSC) is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays. The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates. Early-stage programs include iPSC-derived NK cell candidates engineered for enhanced tumor targeting and persistence, alongside T cell programs incorporating novel receptor constructs. Century has established strategic collaborations with leading pharmaceutical partners to advance preclinical research and prepare select programs for clinical evaluation. Founded in 2019 as a spin-out from the Wistar Institute and the University of Pennsylvania, Century Therapeutics is headquartered in Philadelphia. Since its inception, the company has built multidisciplinary teams across research, manufacturing and regulatory affairs. Century’s leadership brings experience from established biopharmaceutical companies and academic institutions, supporting its goal of delivering transformative cell therapies to patients worldwide.View Century Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Home Depot’s Sell-Off Could Become a Huge OpportunityBrady Corp Wires Up a Massive AI-Powered BreakoutDillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade?Why Applied Optoelectronics Stock May Be Near a Turning PointIs Everspin Technologies the Next AI Edge Breakout?Peloton Stock Gives Back Gains After Upbeat Earnings ReportDatavault Gains Traction: 5 Reasons to Sell Now Upcoming Earnings NetEase (5/21/2026)Ross Stores (5/21/2026)Walmart (5/21/2026)Deere & Company (5/21/2026)Mitsubishi UFJ Financial Group (5/21/2026)AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
